HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.8.3
  1. Home
  2. /Compound

Mycophenolic Acid

HCID 446541
New reaction
Print

Completing data — refresh the page later to see the latest

Basic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Substructure searchFind similar structures

Basic information

CAS
24280-93-1
Standard SMILES
COc1c(C)c2c(c(O)c1C/C=C(\C)CCC(=O)O)C(=O)OC2
InChIKey
HPNSFSBZBAHARI-RUDMXATFSA-N
Molecular formula
C17H20O6
Average molar mass
320.3 g/mol
Monoisotopic mass
320.12598835

Overview

Mycophenolic acid is a member of the class of 2-benzofurans that is 2-benzofuran-1(3H)-one which is substituted at positions 4, 5, 6, and 7 by methyl, methoxy, (2E)-5-carboxy-3-methylpent-2-en-1-yl, and hydroxy groups, respectively. It is an antibiotic produced by Penicillium brevi-compactum, P. stoloniferum, P. echinulatum and related species. An immunosuppressant, it is widely used (partiularly as its sodium salt and as the 2-(morpholin-4-yl)ethyl ester prodrug, mycophenolate mofetil) to prevent tissue rejection following organ transplants and for the treatment of certain autoimmune diseases. It has a role as an anticoronaviral agent, a mycotoxin, an antimicrobial agent, an antineoplastic agent, a xenobiotic, an immunosuppressive agent, an EC 1.1.1.205 (IMP dehydrogenase) inhibitor, a Penicillium metabolite and an environmental contaminant. It is a monocarboxylic acid, a member of phenols, a gamma-lactone and a member of 2-benzofurans. It is functionally related to a hex-4-enoic acid. It is a conjugate acid of a mycophenolate.

Names & identifiers

Preferred name
Mycophenolic Acid
IUPAC
(E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1H-2-benzofuran-5-yl)-4-methylhex-4-enoic acid
English name
Mycophenolic acid
Molecular formula
C17H20O6
Molecular weight
320.34

Names & synonyms

mycophenolic acid24280-93-1MelbexMycophenolsaeureLilly-68618Acido micofenolicoAcide mycophenoliqueNSC-129185Micofenolico acidoAcidum mycophenolicum(4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methylhex-4-enoic acid(E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1H-2-benzofuran-5-yl)-4-methylhex-4-enoic acid
Show more names
Mycophenolic(E)-6-(4-hydroxy-6-Methoxy-7-Methyl-3-oxo-1,3-dihydroisobenzofuran-5-yl)-4-Methylhex-4-enoic acidMycophenoLMycophenolate Mofetil EP Impurity F68618Mycophenolinsuremicofenolicoacido
Ly 68618(E)-6-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoic acidDTXSID4041070HU9DX48N0TDTXCID2021070NSC1291854-Hexenoic acid, 6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-, (E)-4-Hexenoic acid, 6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-, (E)-

Properties

Computed structural propertiesFilling in

XLogP
3.2
Topological polar surface area
93.1 Ų
Hydrogen bond donors
2
Hydrogen bond acceptors
6
Rotatable bonds
6
Heavy atoms
23
Formal charge
0
Complexity
485

Experimental & physicochemical properties

Drugs · 6 items

Pharmaceutical

Pharmaceuticals -> Antibiotics

Pharmaceuticals

Pharmaceuticals -> Listed in ZINC15

Pharmaceuticals -> Metabolite of Mycophenolate mofetil

Pharmaceuticals -> Used in Switzerland

LogP · 2 items

2.8

2.76

Solubility · 2 items

Insoluble

3.55e-02 g/L

Human DrugsBreast Feeding; Lactation; Milk, Human; Immunosuppressive Agents
Endocrine DisruptorsPotential endocrine disrupting compound
Melting Point · 2 items

141°C

141 °C

Physical DescriptionSolid
Collision Cross Section · 2 items

165.4 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

Safety & regulation

Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.

GHS classification

GHS Classification · 4 items

Danger

H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]

P203, P260, P264, P270, P273, P280, P301+P317, P318, P319, P330, P391, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 89 reports by companies from 17 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Hazard information

Regulatory Information · 2 items

REACH registered substance: Mycophenolic acid (EC: 246-119-3)

4-Hexenoic acid, 6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-, (4E)-: Does not have an individual approval but may be used under an appropriate group standard

Hazard Classes and CategoriesAcute Tox. 4 (100%)

Toxicology

Exposure RoutesBioavailability following oral administration of Myfortic delayed-release tablet ranges from 70-95%
Toxicity Summary · 1 item

Mycophenolic acid is a potent, selective, uncompetitive, and reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH), and therefore inhibits the de novo pathway of guanosine nucleotide synthesis without incorporation into DNA. Because T- and B-lymphocytes are critically dependent for their proliferation on de novo synthesis of purines, whereas other cell types can utilize salvage pathways, mycophenolic acid has potent cytostatic effects on lymphocytes. Mycophenolic acid inhibits proliferative responses of T- and B-lymphocytes to both mitogenic and allospecific stimulation. Addition of guanosine or deoxyguanosine reverses the cytostatic effects of mycophenolic acid on lymphocytes. Mycophenolic acid also suppresses antibody formation by B-lymphocytes. Mycophenolic acid prevents the glycosylation of lymphocyte and monocyte glycoproteins that are involved in intercellular adhesion to endothelial cells and may inhibit recruitment of leukocytes into sites of inflammation and graft rejection.

Chemistry & industry

Pharmacology

ATC Code · 3 items

L04AA06

L - Antineoplastic and immunomodulating agents

QL - Antineoplastic and immunomodulating agents

Protein BindingMycophenolic acid is highly protein-bound, and more than 98% of it is bound to albumin.
Pharmacodynamics · 1 item

Mycophenolic acid is a potent inhibitor of inosine monophosphate dehydrogenase (IMPDH) that blocks _de novo_ biosynthesis of purine nucleotides. This affects lymphocytes primarily and leads to the suppression of DNA synthesis in T- and B-cells. Mycophenolic acid arrests the T-lymphocyte cell cycle at the G1/S interface and inhibits the proliferation of lymphocytes. Also, it has been suggested that mycophenolic acid suppresses cytokine production by limiting the number of cytokine-producing cells. The enteric-coating of mycophenolic acid tablets prevents the development of upper gastrointestinal adverse events by delaying drug release until it reaches the small intestine. Patients treated with mycophenolic acid have a higher risk of developing new or reactivated viral infections, serious infections, blood dyscrasias (including pure red cell aplasia), serious gastrointestinal tract complications, acute inflammatory syndrome associated with mycophenolate products, lymphoma, and other malignancies. The use of mycophenolic acid is also associated with an increased risk of first-trimester pregnancy loss and congenital malformations. Mycophenolic acid should be avoided in patients with rare hereditary deficiency of hypoxanthine-guanine phosphoribosyl-transferase (HGPRT). Patients treated with mycophenolic acid should not receive live attenuated vaccines or donate blood or semen.

Mechanism of Action · 1 item

Mycophenolic acid is a selective noncompetitive and reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH), that blocks the conversion of inosine-5-phosphate and xanthine-5-phosphate to guanosine-5-phosphate. By inhibiting IMPDH, mycophenolic acid interferes with the _de novo_ pathway of guanosine nucleotide synthesis without incorporation into DNA. While other cell types are able to use salvage pathways, T- and B-lymphocyte proliferation is a mechanism heavily dependent on the _de novo_ synthesis of purines. Therefore, mycophenolic acid has potent cytostatic effects on T- and B- and lymphocytes. Mycophenolic acid also suppresses antibody formation by B-lymphocytes and prevents the glycosylation of lymphocyte and monocyte glycoproteins involved in intercellular adhesion to endothelial cells.

Related reactions

18 records
New reaction record
HRID 4501 reaction equation
HRID 4501As reactant
HRID 580450 reaction equation
HRID 580450As reactant
HRID 900063 reaction equation
HRID 900063As reactant
HRID 1253194 reaction equation
HRID 1253194As reactant
HRID 1382760 reaction equation
HRID 1382760As reactant
HRID 1607869 reaction equation
HRID 1607869As reactant
HRID 1645775 reaction equation
HRID 1645775As reactant
HRID 1709156 reaction equation
HRID 1709156As reactant
PreviousPage 1 of 3

Compound notes

On this pageBasic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes

Database identifiers

CAS
24280-93-1、483-60-3
PubChem CID
446541
DTXSID
DTXSID4041070
ChEMBL
CHEMBL866
ChEBI
CHEBI:168396
UNII
HU9DX48N0T
EC Number
246-119-3
Nikkaji
J2.768E、J49.437B

176 Ų [M+NH4]+ [CCS Type: TW; Method: calibrated with polyalanine]

Physicochemical properties

Melting point
141 °C · 141°C
Boiling point
419.24 °C · 419.24°C (rough estimate)
Density
1.23 · 1.2300 (rough estimate)
vapor pressure
0 Pa · 0Pa at 22℃
refractive index
1.52 · 1.5200 (estimate)
Flash point
2 ℃ · 2℃
storage temp.
-20 °C · Sealed in dry,Store in freezer, under -20°C
solubility
50 mg/mL, · methanol: 50 mg/mL, clear, colorless to faintly yellow
form
powder
pka
4.5 · 4.5(at 25℃)
color
white to white with yellow cast
Water Solubility
13 mg/L · 13mg/L(25 ºC)
Merck
14 · 14,6327
BRN
1295848 · 1295848
BCS Class
2 · 2
Stability
2 years · Stable for 2 years from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20° for up to 3 months.
Major Application
clinical testing
InChI
1S/C17H20O6/c1-9(5-7-13(18)19)4-6-11-15(20)14-12(8-23-17(14)21)10(2)16(11)22-3/h4,20H,5-8H2,1-3H3,(H,18,19)/b9-4+
InChIKey
HPNSFSBZBAHARI-RUDMXATFSA-N
SMILES
COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(O)=O
LogP
-1.83 · -1.83-2.28 at 25℃ and pH5-9
Dissociation constant
4.58 · 4.58-8.05 at 22.5-25℃
CAS DataBase Reference
24280 · 24280-93-1(CAS DataBase Reference)
FDA UNII
9 DX48N0T · HU9DX48N0T
NCI Drug Dictionary
mycophenolic acid
ATC code
4 AA06 · L04AA06
EPA Substance Registry System
4 · 4-Hexenoic acid, 6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-, (4E)- (24280-93-1)
UNSPSC Code
41116107 · 41116107
NACRES
77 · NA.77
Symbol(GHS)
7 · GHS07,GHS08,GHS09
Signal word
Danger
Hazard statements
302 · H302-H341-H360D-H372-H410
Precautionary statements
201 · P201-P202-P260-P273-P301+P312-P308+P313
Hazard Codes
Xn,N,T,F
Risk Statements
22 · 22-61-40-68-50/53-48/25-52/53-36-20/21/22-11
Safety Statements
53 · 53-45-36/37-61-22-26-16
RIDADR
2811 · 2811
WGK Germany
3 · 3
RTECS
8050000 · MP8050000
F
10 · 10
HazardClass
6.1 · 6.1(b)
PackingGroup
III
HS Code
29419090 · 29419090
Storage Class
3 · 3 - Flammable liquids
Hazard Classifications
4 DermalAcute · Acute Tox. 4 DermalAcute Tox. 4 InhalationAcute Tox. 4 OralAquatic Chronic 3Eye Irrit. 2Flam. Liq. 2
Toxicity
50 in · LD50 in mice (mg/kg): >1250 orally; 972.9±77 i.p. (Williams)
REACH Registrations
Active
Limited Quantities
5 kg · 5.0 kg (11 lbs) (solid)
Excepted Quantities
Max Inner Pack (30g or 30ml) and Max Outer Pack (1Kg or 1L)
Signs and SymptomsPossible signs and symptoms of acute overdose could include the following: hematological abnormalities such as leukopenia and neutropenia, and gastrointestinal symptoms such as abdominal pain, diarrhea, nausea and vomiting, and dyspepsia.
Carcinogen ClassificationNo indication of carcinogenicity to humans (not listed by IARC).
Effects During Pregnancy and Lactation◉ Summary of Use during Lactation
Toxicity DataLD50: 352 mg/kg (Oral, Rat) (A308) LD50: 1000 mg/kg (Oral, Mouse) (A308) LD50: >6000 mg/kg (Oral, Rabbit) (A308)
EPA Human Health Benchmarks for Pharmaceuticals · 6 items

Mycophenolic acid

33.6

142.0

The recommended dose of mycophenolic acid is 720 mg administered twice daily (1440 mg total daily dose).

Data used to generate the benchmarks include the following: Lowest Daily Dose (LDD): 1440 mg/day, Lowest Therapeutic Dose (LTD): 18.0 mg/kg-day, and Screening Dose: 0.006 mg/kg-day.

11-Nov-20

Safety data

F
10
wgk
3
rtecs
MP8050000
ridadr
2811
hs_code
29419090
Toxicity
LD50 in mice (mg/kg): >1250 orally; 972.9±77 i.p. (Williams)
risk_code
22-61-40-68-50/53-48/25-52/53-36-20/21/22-11
Signal word
Danger
Symbol(GHS)
GHS07,GHS08,GHS09
hazard_code
Xn,N,T,F
safety_code
53-45-36/37-61-22-26-16
hazard_class
6.1(b)
Storage Class
3 - Flammable liquids
packing_group
III
Hazard statements
H302-H341-H360D-H372-H410
Limited Quantities
5.0 kg (11 lbs) (solid)
Excepted Quantities
Max Inner Pack (30g or 30ml) and Max Outer Pack (1Kg or 1L)
REACH Registrations
Active
Hazard Classifications
Acute Tox. 4 DermalAcute Tox. 4 InhalationAcute Tox. 4 OralAquatic Chronic 3Eye Irrit. 2Flam. Liq. 2
Precautionary statements
P201-P202-P260-P273-P301+P312-P308+P313
Biological Half-LifeThe mean elimination half-life of mycophenolic acid ranges between 8 and 16 hours, while the mean elimination half-life of mycophenolic acid glucuronide, its major metabolite, ranges between 13 and 17 hours.
Metabolism/Metabolites · 3 items

Mycophenolic acid is mainly metabolized by glucuronyl transferase to form glucuronidated metabolites. Mycophenolic acid glucuronide (MPAG), the major metabolite of mycophenolic acid, does not display pharmacological activity. However, the acyl glucuronide minor metabolite has a pharmacological activity similar to mycophenolic acid. The AUC ratio of mycophenolic acid:MPAG:acyl glucuronide is approximately 1:24:0.28 at a steady state.

Mycophenolic acid has known human metabolites that include 6-O-desmethyl-MPA (DM-MPA) and Mycophenolic acid glucuronide.

Mycophenolic acid is metabolized mainly by glucuronyl transferase to glucuronidated metabolites, predominantly the phenolic glucuronide, mycophenolic acid glucuronide (MPAG). MPAG does not manifest pharmacological activity. The acyl glucuronide minor metabolite has pharmacological activity similar to mycophenolic acid. The AUC ratio of Mycophenolic acid:MPAG:acyl glucuronide is approximately 1:24:0.28 at steady state. Half Life: The mean elimination half-life for mycophenolic acid ranges from 8-16 hours, while that of the MPAG metabolite ranges from 13-17 hours.

FDA Pharmacological Classification · 6 items

HU9DX48N0T

MYCOPHENOLIC ACID

Established Pharmacologic Class [EPC] - Antimetabolite Immunosuppressant

Mycophenolic acid is an Antimetabolite Immunosuppressant.

MYCOPHENILIC ACID

Antimetabolite Immunosuppressant [EPC]

MeSH Pharmacological Classification · 3 items

Chemical substances, produced by microorganisms, inhibiting or preventing the proliferation of neoplasms.

Substances obtained from various species of microorganisms that are, alone or in combination with other agents, of use in treating various forms of tuberculosis; most of these agents are merely bacteriostatic, induce resistance in the organisms, and may be toxic.

Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction.

Absorption, Distribution and Excretion · 4 items

Between 360 mg and 2,160 mg, mycophenolic acid follows a linear and dose-proportional pharmacokinetic profile. The enteric-coating of mycophenolic acid tablets prevents release under acidic conditions (stomach, pH < 5). However, enteric-coated mycophenolic acid tablets are highly soluble in neutral pH conditions such as those in the intestine. In renal transplant patients, the median delay (Tlag) in the rise of mycophenolic acid concentration ranged between 0.25 and 1.25 hours, and the Tmax ranged between 1.5 and 2.75 hours. Adult renal transplant patients on cyclosporine given mycophenolic acid had a Tmax of 2 h, a Cmax of 26.1 μg/mL, and an AUC0-12 of 66.5 μg⋅h/mL. Stable pediatric (5-16 years old) renal transplant patients had a Cmax and AUC 33% and 18% higher than the ones detected in adults. In stable renal transplant patients treated with cyclosporine, the gastrointestinal absorption and absolute bioavailability of delayed-release tablets of mycophenolic acid were 93% and 72%, respectively. Following the administration of a high-fat meal (55 g fat, 1000 calories), the AUC of mycophenolic acid (enteric-coated tablets, 720 mg) was comparable to the one detected during fasting. However, a high-fat meal can lead to a 33% decrease of the Cmax, a 3.5-hour delay in the Tlag (range of -6 to 18 hours), and a 5.0-hour delay in the Tmax (range of -9 to 20 hours). To avoid variability in the absorption of mycophenolic acid, this drug should be taken on an empty stomach.

In stable renal transplant patients, approximately 60% of mycophenolic acid is eliminated in the urine as mycophenolic acid glucuronide (MPAG), while 3% is eliminated unchanged. MPAG is also secreted in the bile and is available for deconjugation by gut flora. The mycophenolic acid that results from MPAG deconjugation may be reabsorbed and produce a second peak 6-8 hours after administration.

At steady state, the volume of distribution of mycophenolic acid is 54 L. At the elimination phase, the volume of distribution of mycophenolic acid is 112 L.

The mean clearance of mycophenolic acid is 140 mL/min. The mean renal clearance of its metabolite, mycophenolic acid glucuronide, is 15.5 mL/min.

Tissue LocationsKidney
Cellular LocationsMembrane
Metabolite PathwaysMycophenolic Acid Metabolism Pathway

Uses & manufacturing

Uses · 2 items

Use (kg; approx.) in Germany (2009): ?2500

For the prophylaxis of organ rejection in patients receiving allogeneic renal transplants, administered in combination with cyclosporine and corticosteroids.

Applications · 7 items

DescriptionMycophenolic acid(24280-93-1), less accurately called mycophenolate, is a compound derived from Penicillium stoloniferum and related species. It can reversibly inhibit inosine monophosphate dehydrogenase (IMPDH), the enzyme that controls the rate of synthesis of guanine monophosphate in the de novo pathway of purine synthesis used in the proliferation of B and T lymphocytes. Mycophenolic acid also has antibacterial, anticancer, antifungal, and antiviral activities. These powerful properties have been exploited in studies on organ transplant survival, anti-proliferative, rheumatoid arthritis, and psoriasis. It was initially marketed as the prodrug mycophenolate mofetil (MMF) to improve oral bioavailability. More recently, the salt mycophenolate sodium has also been introduced. Mycophenolate mofetil is marketed under the trade name CellCept and mycophenolate sodium as Myfortic. Discovered by an Italian medical scientist Bartolomeo Gosio in 1893, mycophenolic acid was the first antibiotic to be synthesised in pure and crystalline form. But its medical application was forgotten until two American scientists C.L. Alsberg and O.M. Black resynthesised it in 1912, and gave its chemical name. It was eventually found to be a broad-spectrum acting drug having antiviral, antifungal, antibacterial, anticancer, and antipsoriasis properties. The clinically usable drug Cellcept was developed by South African geneticist Anthony Allison and his wife Elsie M. Eugui. It was first approved by the US Food and Drug Administration on 3 May 1995 for use in kidney transplantation.

DescriptionMycophenolic acid is an immunosuppresive microbial metabolite that has been found in P. brevicompactum. It is also an active metabolite of mycophenolate mofetil that is formed via carboxylesterase 1 (CES1) and CES2. Mycophenolic acid is an inhibitor of IMP dehydrogenase (IMPDH) type I and type II (IC50s = 32 and 11 nM, respectively, in cell-free assays) and inhibits DNA synthesis in L strain mouse fibroblasts when used at concentrations ranging from 0.1 to 10 μg/ml. It is active against several strains of C. albicans, C. parakrusei, C. tropicalis, and C. neoformans (MICs = 3.9-31.25 μg/ml), as well as various strains of S. aureus (MICs = 31.25-125 μg/ml). Mycophenolic acid (150 mg/kg) reduces splenomegaly in a mouse model of Friend virus-induced leukemia. It decreases the number of hemolytic plaque forming cells isolated from the spleen of mice immunized with sheep red blood cells (RBCs) when administered at doses ranging from 60 to 240 mg/kg. Formulations containing mycophenolic acid have been used as immunosuppressive agents in the prevention of organ transplant rejection.

UsesAn antibiotic produced by Penicillium brevi-compactum, P. Stoloniferum and related spp. A selective inhibitor of lymphocyte proliferation by blocking inosine monophosphate dehydrogenase, an enzyme involved in the de novo synthesis of purine nucleotides.

Usesimmune suppressant, antineoplastic, antiviral

Usesantineoplastic, progestin

UsesMycophenolic acid is a common Penicillium metabolite first reported in the 1930s as a possible mycotoxin. Re-investigation showed mycophenolic acid to display broad antitumour, antiviral, antifungal and antiprotozoan activities. Its potent immunosuppressant activity led to its commercial development to prevent kidney transplant rejection. Mycophenolic acid acts by inhibiting inosine monophosphate dehydrogenase, controlling the rate of de novo purine synthesis in proliferating B and T lymphocytes.

General DescriptionAssayed in therapeutic drug monitoring to ensure patients remain within the drug′s therapeutic range, mycophenolic acid is an immunosuppressant drug and the active metabolite of the prodrug mycophenolate mofetil. This analytical standard is suitable for LC-MS/MS applications including therapeutic drug monitoring and other clinical or diagnostic applications.

Upstream & downstream products

Downstream products

6-(4,6-Dihydroxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-4-methyl-hex-4-enoic acid methyl esterMethyl Mycophenolate (EP Impurity E)Mycophenolic Acid Acyl-β-D-glucuronide Allyl Ester
Additional notes · 1 item

DefinitionChEBI: A member of the class of 2-benzofurans that is 2-benzofuran-1(3H)-one which is substituted at positions 4, 5, 6, and 7 by methyl, methoxy, (2E)-5-carboxy-3-methylpent-2-en-1-yl, and hydroxy groups, respectively. It is an antibiotic produced by Penicillium brevi-compactum, P. stoloniferum, P. echinulatum and related species. An immunosuppressant, it is widely used (partiularly as its sodium salt and as the 2-(morpholin-4-yl)ethyl ester prodrug, mycophenolate mo etil) to prevent tissue rejection following organ transplants and for the treatment of certain autoimmune diseases.